Semaglutide: A Comprehensive Review of its Pharmacology, Clinical Applications, and Future Therapeutic Potential
Abstract
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that works for an extended period of time and has revolutionized the treatment of type 2 diabetes mellitus and obesity. By mimicking the endogenous incretin hormone GLP-1, semaglutide has a variety of physiological effects that help to improve metabolic control. It increases glucose-dependent insulin secretion while also reducing inappropriate appetite. Glucagon release, delayed gastric emptying, and increased satiety combine to produce better glycemic management and considerable weight reduction. Semaglutide differs from prior GLP-1 analogs in a crucial way: it comes in both subcutaneous injectable and oral tablet formulations, giving patients more options and ease. for patients, increasing adherence and long-term treatment outcomes.
Semaglutide has a long half-life of about a week, which makes it possible to administer the injectable form once a week. Its oral composition makes use of absorption-enhancing technology, which, despite the molecule's peptide composition, aids in gastrointestinal absorption. Its greater effectiveness in lowering glycated haemoglobin (HbA1c), decreasing body weight, and lowering the risk has been demonstrated by clinical trials, such as the SUSTAIN and PIONEER programs. of significant negative cardiovascular events when compared with conventional treatments. Mild to moderate gastrointestinal discomfort, such as nausea and vomiting, is a common side effect, and it typically subsides with time.
Beyond diabetes and obesity, emerging evidence suggests semaglutide’s potential in addressing metabolic-associated steatotic liver disease, cardiovascular prevention, and neuroprotective applications. As research advances, semaglutide continues to exemplify the integration of peptide pharmacology and innovative drug delivery, marking a milestone in personalized management of metabolic disorders.
Keywords: Semaglutide, GLP-1 receptor agonist, type 2 diabetes mellitus, obesity, SNAC [sodium N–(8-[2-hydroxybenzoyl] amino)caprylate] , STEP program.
Keywords:
Semaglutide, GLP-1 receptor agonist, type 2 diabetes mellitus, obesity, SNAC [sodium N–(8-[2-hydroxybenzoyl] amino)caprylate] , STEP programDOI
https://doi.org/10.22270/jddt.v15i12.7452References
1. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-701. https://doi.org/10.2337/dci18-0033 PMid:30291106 PMCid:PMC6245208
2. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes 2019. Diabetes Care. 2019;42(Suppl 1):S90-S102. https://doi.org/10.2337/dc19-S009 PMid:30559235
3. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-80. https://doi.org/10.1021/acs.jmedchem.5b00726 PMid:26308095
4. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. https://doi.org/10.3389/fendo.2019.00155 PMid:31031702 PMCid:PMC6474072
5. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55(5):497-504. https://doi.org/10.1002/jcph.443 PMid:25475122 PMCid:PMC4418331
6. Jensen L, Helleberg H, Rofel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;108:101-10. https://doi.org/10.1016/j.ejps.2017.03.020
7. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. https://doi.org/10.1126/scitranslmed.aar7047 PMid:30429357
8. Granhall C, Donsmark M, Blicher TM, Golor G, Søndergaard FL, Thomsen M, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781-91. https://doi.org/10.1007/s40262-018-0728-4 PMid:30565096
9. Buckley ST, Schéele SG, Kirk RK, Knudsen LB. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide. Diabetes. 2017;66(Suppl 1):A322.
10. Neumiller JJ. Incretin-based therapies. Med Clin North Am. 2015;99(1):107-29. https://doi.org/10.1016/j.mcna.2014.08.013 PMid:25456646
11. Buckley ST, Schéele SG, Kirk RK, Knudsen LB. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide. Diabetes. 2017;66(Suppl 1):A322.
12. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. https://doi.org/10.1126/scitranslmed.aar7047 PMid:30429357
13. European Medicines Agency. Rybelsus: Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf.
14. Connor A, Donsmark M, Hartoft-Nielsen ML, Søndergaard FL, Bækdal TA. A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):S319.
15. Bækdal TA, Borregaard J, Donsmark M, Breitschaft A, Søndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):A315.
16. Maarbjerg SJ, Borregaard J, Breitschaft A, Donsmark M, Søndergaard FL. Evaluation of the effect of food on the pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):A321.
17. Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Bækdal T. A drug-drug interaction trial of oral semaglutide with levothyroxine and multiple co-administered tablets. J Endocr Soc. 2019;3(Suppl 1):SAT-140. https://doi.org/10.1210/js.2019-SAT-140 PMCid:PMC6552044
18. Overgaard RV, Navarria A, Hertz CL, Ingwersen SH. Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide. Diabetes Technol Ther. 2020;22(Suppl 1):A187-8.
19. Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571-80. https://doi.org/10.1007/s40262-018-0649-2 PMid:29623579 PMCid:PMC6267549
20. Baekdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314-23. doi:10.1002/jcph.1131. https://doi.org/10.1002/jcph.1131 PMid:29693715 PMCid:PMC6175428
21. Bækdal TA, Breitschaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14(8):869-77. https://doi.org/10.1080/17425255.2018.1488965 PMid:29897249
22. Bækdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193-203. https://doi.org/10.1007/s40262-019-00756-2 PMid:30945118 PMCid:PMC6719321
23. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: A randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-48. https://doi.org/10.1016/S0140-6736(21)00845-X PMid:33894838
24. Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am J Health Syst Pharm. 2016;73(19):1493-507. https://doi.org/10.2146/ajhp150990 PMid:27521241
25. US Food and Drug Administration. FDA requests the withdrawal of weight-loss drug Belviq, Belviq XR (Lorcaserin) from the market: Potential risk of cancer outweighs the benefits. Center for Drug Evaluation and Research. Washington DC; 2020.
26. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183 PMid:33567185
27. Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291-301. https://doi.org/10.1210/jc.2018-00070 PMid:29688502 PMCid:PMC5991220
28. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-60. https://doi.org/10.1016/S2213-8587(17)30013-X PMid:28110911
29. Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): A randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-67. https://doi.org/10.1016/S2213-8587(19)30066-X PMid:30833170
30. Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. Pioneer 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-32. https://doi.org/10.2337/dc19-0749 PMid:31186300
31. Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): A placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515-27. https://doi.org/10.1016/S2213-8587(19)30192-5 PMid:31189517
32. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-51. https://doi.org/10.1056/NEJMoa1901118 PMid:31185157
33. Center for Drug Evaluation and Research. Guidance for industry: Developing products for weight management. Washington DC: FDA; 2007. Available from: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071612.pdf .
34. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA. 2016;315(22):2424-34. https://doi.org/10.1001/jama.2016.7602 PMid:27299618 PMCid:PMC5617638
35. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-43. https://doi.org/10.1002/oby.20309 PMid:23408728 PMCid:PMC3739931
36. Finer N, James WPT, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306-13. https://doi.org/10.1038/sj.ijo.0801128 PMid:10757623
37. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330-42. https://doi.org/10.1038/oby.2011.330 PMid:22051941 PMCid:PMC3270297
38. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-77. https://doi.org/10.1210/jc.2011-1256 PMid:21795446
39. Lyseng-Williamson KA. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Their uses and differential features. Clin Drug Investig. 2019;39(8):805-19. https://doi.org/10.1007/s40261-019-00826-0 PMid:31317516 PMCid:PMC6746674
40. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44. https://doi.org/10.1056/NEJMoa1607141 PMid:27633186
41. Granhall C, Donsmark M, Blicher TM, Golor G, Søndergaard FL, Thomsen M, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781-91. https://doi.org/10.1007/s40262-018-0728-4 PMid:30565096
42. Overgaard RV, Navarria A, Hertz CL, Ingwersen SH. Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide. Diabetes Technol Ther. 2020;22(Suppl 1):A187-8.
43. Baekdal TA, Borregaard J, Donsmark M, Breitschaft A, Søndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):A315.
44. Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571-80. https://doi.org/10.1007/s40262-018-0649-2 PMid:29623579 PMCid:PMC6267549
45. Baekdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314-23. https://doi.org/10.1002/jcph.1131 PMid:29693715 PMCid:PMC6175428
46. Bækdal TA, Breitschaft A, Navarria A, Hansen CW. Effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14(8):869-77. https://doi.org/10.1080/17425255.2018.1488965 PMid:29897249
47. Bækdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of oral semaglutide on pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193-203. https://doi.org/10.1007/s40262-019-00756-2 PMid:30945118 PMCid:PMC6719321
48. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management: A randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-48. https://doi.org/10.1016/S0140-6736(21)00845-X PMid:33894838
49. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-51. https://doi.org/10.1056/NEJMoa1901118 PMid:31185157
Published
Abstract Display: 289 
PDF Downloads: 185 PDF Downloads: 80 How to Cite
Issue
Section
Copyright (c) 2025 Shalvi Sunil Pawar , Pooja Balkrishna Rasal , Kiran Hemant Kulkarni , Suyash Balasaheb Pawar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.